Appendix A - World Health Organization Trial Registration Data Set

Data category	**Information**[32]
Primary registry and trial identifying number	ClinicalTrials.gov NCT04892199
Date of registration in primary registry	03/01/2021
Secondary identifying numbers	The Regional Committee on Research Ethics (journal number H-20019008) and the Danish Medicines Agency (EudraCT: 2020-000102-28).
Source(s) of monetary or material support	Novo Nordisk A/S, Mental Health Services CPH, Copenhagen, Denmark, The Novo Nordisk Foundation, The Lundbeck Foundation, The P. Carlsen Foundation, and The Dagmar Marshalls Foundation supported the project with Scholarship grants.
Primary sponsor	Novo Nordisk A/S
Secondary sponsor(s)	Mental Health Services CPH, Copenhagen, Denmark, The Novo Nordisk Foundation, The Lundbeck Foundation, The P. Carlsen Foundation, and The Dagmar Marshalls Foundation supported the project with Scholarship grants.
Contact for public queries	Anders Fink-Jensen MD, DMSc, Psychiatric Centre Copenhagen, Rigshospitalet, Copenhagen University Hospital, Denmark Tel: +45 2275 5843. E-mail: anders.fink-jensen@regionh.dk
Contact for scientific queries	Anders Fink-Jensen MD, DMSc, Psychiatric Centre Copenhagen, Rigshospitalet, Copenhagen University Hospital, Denmark Tel: +45 2275 5843. E-mail: anders.fink-jensen@regionh.dk

Data category	**Information**[32]
Public title	GLP-1 receptor therapy for antipsychotic-induced metabolic disturbances in patients diagnosed with schizophrenia
Scientific title	Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine or olanzapine-treated patients with schizophrenia (SemaPsychiatry): a randomised clinical trial
Countries of recruitment	Denmark
Health condition(s) or problem(s) studied	Schizophrenia Prediabetes Diabetes Metabolic disturbances Clozapine Olanzapine
Intervention(s)	Active comparator: Semaglutide 1.34 mg/ml, 1.5 ml pre-filled pen-injector is supplied in pens for injection containing 2.0 mg of the GLP-1RA semaglutide in 1.5 ml sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Placebo comparator: The semaglutide placebo pens contain no active drug and are administered in the same way and volume as semaglutide.
Key inclusion and exclusion criteria	Inclusion criteria: 1. Informed oral and written consent. 2. Diagnosed with schizophrenia according to the criteria of ICD10 (International Classification of Diseases, World Health Organization (WHO)) or the DSM-V (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, the American Psychiatric Association. 3. Initiating current daily treatment with clozapine or olanzapine, respectively, within 60 months. 4. Age 18 years to 65 years (both included). 5. Body mass index (BMI) ≥25 kg/m2. 6. Diagnosed with prediabetes or type 2 diabetes, with the following plasma levels: Prediabetes: HbA1c 35-47 mmol/mol or Type 2 diabetes: HbA1c 48-57 mmol/mol. Exclusion criteria:

Data category	**Information**[32]
	1. Acute worsening of psychosis based on a clinical evaluation (score of 6 or 7 on the CGI-S scale). 2. Coercive measures 3. Females of child-bearing potential who are pregnant, breastfeeding, or have the intention of becoming pregnant. 4. Women who are not willing to use an adequate contraceptive during the full length of the study. 5. Patients treated with corticosteroids or other hormone therapy (except oestrogens). 6. Any active substance abuse or dependence (except for nicotine). 7. Impaired hepatic function (plasma liver transaminases >2 times upper normal limit). 8. Impaired renal function (serum creatinine >150 µmol/l and/or macroalbuminuria). 9. Impaired pancreatic function (acute or chronic pancreatitis and/or plasma amylase >2 times upper normal limit). 10. Cardiac problems defined as decompensated heart failure (NYHA class III/IV), unstable angina pectoris, and/or myocardial infarction within the last 12 months. 11. Hypertension with systolic blood pressure >180 mmHg or diastolic blood pressure >100 mmHg. 12. Any condition that the investigator feels would interfere with trial participation. 13. Receiving any experimental or pre-marketing drug within the last 3 months. 14. Use of weight-lowering pharmacotherapy within the preceding 3 months. 15. Known type 1 diabetes. 16. Suicidal behavior as judged by the investigator and based on clinical evaluation. 17. Plasma HbA1c > 57 mmol/mol (tested twice) in which case the patient will be excluded from the study and transferred to general practitioner or hospital for diabetic treatment. 18. Any known contraindication towards the treatment with semaglutide.
Study type	Interventional Allocation: randomized Intervention model: parallel assignment Masking: double blind (subject, investigator, outcomes assessor) Primary purpose: treatment efficacy Phase 4

Data category	**Information**[32]
Date of first enrolment	September 2021
Target sample size	104
Recruitment status	Recruiting
Primary outcome(s)	HbA1c
Key secondary outcomes	Body weight, hip and waist circumference Blood pressure and pulse Peptide hormone Insulin sensitivity and beta cell function Incretin hormone Lipid profile Hepatic function Reward value of sweet-fat stimulus Bone markers Body composition and bone density Psychopathology Activity measurements Alcohol, tobacco and drug use Proteomic analyses and measurement of oxidative stress